Basic Approach for the Development of Molecular Target Therapy for Autoimmune Diseases and Immune-Mediated Disorders.

我们有识别的鱼子酱-1作为CD 26的成本模拟配体。The 82- 101 th amino acid （a·a） of caveolin-1 bound to the 201- 211 th a·a of CD26 with the DPPIV cat？tic site of 630^<th>a·a， Serine。Moreover，我们发现了CD 26与CARMA-1在T细胞中相互作用的细胞塑料尾，结果在成本模拟信号的定义中。在人类PBL进入SCID老鼠后，Xeno-GVHD的象征被诱导，人类T细胞在x-GVHD效应的病理学中扮演了一个角色。用人类CD 26抗体在改进x-GVHD的症状中发现的这些X-GVHD老鼠的治疗，建议对人体免疫介导疾病的有效治疗进行抗CD 26治疗，如自动免疫紊乱和GVHD后的治疗。

We have identified caveolin-1 as the costimulatory ligand for CD26. The 82-101th amino acid (a・a) of caveolin-1 bound to the 201-211th a・a of CD26 with the DPPIV catalytic site of 630^<th> a・a, Serine. Moreover, we found that cytoplasmic tail of CD26 interacts with CARMA-1 in T cells, resulting in the induction of costimulatory signal. After injection of human PBL into SCID mice, the symptom of xeno-GVHD has been induced and human T cells play a role in pathophysiology of x-GVHD as effectors. Treatment of these x-GVHD mice with humanized CD26 antibody resulted in improvement of the symptom of x-GVHD, suggesting that anti-CD26 treatment leads to the effective treatment of human immune-mediated diseases such as autoimmune disorders and GVHD after allo-BMT.